News and Events

Alzheimer's drug announced - but we still need funding for care

  • Posted

Pharmaceutical company Eli Lilly have announced that their drug solanezumab may be able to slow the pace of brain decline for those with early stage Alzheimer’s disease.  Whilst the data provided is  by no means conclusive, the studies seem to indicate that the rate of decline in patients with mild Alzheimer’s was cut by around 34%.  With 44 million people globally suffering from Alzheimer’s even this small hint of a new drug is very exciting.

By 2050 an estimated 135 million people across the globe will have dementia and many of those people will have nursing needs often associated with dementia.  People with high nursing needs may be entitled to funding from the NHS to pay for their care.  This is called NHS Continuing Healthcare funding. Contrary to popular belief, dementia in itself does not automatically entitle someone to NHS Continuing Healthcare funding.  However, the symptoms which will often be the result of dementia such as aggression, inability to communicate, immobility and weight loss due to problems swallowing are the type of things that would be looked at when eligibility for NHS funding is being assessed.

Finding out about NHS Continuing Healthcare funding or Local Authority funding for someone with dementia can be difficult as there is so much out there but, at the same time, each person is assessed on a case by case basis.  Also, finding out this information whilst also having to deal with the fact that a loved one is suffering from dementia can make things even harder.  The first step if you think someone should be eligible for NHS Continuing Healthcare funding is for an assessment to be carried out by an NHS assessor.  If you want to find out more about NHS funding and eligibility visit our page which has a useful FAQ and an online enquiry form for you to fill in.